Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0HNXQI
ADC Name
CN117337196A Compound94
Synonyms
30kmPEG (SCAc-Met (1)xSCAc-Met (1))-2 (Val-Cit-PAB-DEA-SN38)
   Click to Show/Hide
Organization
Shenzhen Enduring Biotech Ltd.
Drug Status
Investigative
Drug-to-Antibody Ratio
1
Structure
Antibody Name
SCAc-Met (1)xSCAc-Met (2)
  Antibody Info 
Antigen Name
Hepatocyte growth factor receptor (MET)
  Antigen Info 
Payload Name
Active metabolite of irinotecan SN38
  Payload Info 
Therapeutic Target
DNA topoisomerase 1 (TOP1)
  Target Info 
Linker Name
30kmPEG-Lys (PEG2 - Mal)-2 (Val-Cit-PAB-DEA)
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
30kmPEG-Lys (PEG2 - Mal)-2 (Val-Cit-PAB-DEA-SN38)
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Cell growth inhibition ratio 
≈ 15
%
CVCL_0186
Pancreatic ductal adenocarcinoma
Cell growth inhibition ratio 
≈ 25
%
CVCL_0186
Pancreatic ductal adenocarcinoma
Cell growth inhibition ratio 
≈ 35
%
CVCL_0186
Pancreatic ductal adenocarcinoma
Cell growth inhibition ratio 
≈ 45
%
CVCL_0186
Pancreatic ductal adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Cell growth inhibition ratio ≈ 15% Positive c-Met expression (c-Met+++/++)
Method Description
c-Met-positive tumor cell line BxPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model Pancreatic ductal adenocarcinoma BxPC3 cells CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Cell growth inhibition ratio ≈ 25% Positive c-Met expression (c-Met+++/++)
Method Description
c-Met-positive tumor cell line BxPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model Pancreatic ductal adenocarcinoma BxPC3 cells CVCL_0186
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Cell growth inhibition ratio ≈ 35% Positive c-Met expression (c-Met+++/++)
Method Description
c-Met-positive tumor cell line BxPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model Pancreatic ductal adenocarcinoma BxPC3 cells CVCL_0186
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Cell growth inhibition ratio ≈ 45% Positive c-Met expression (c-Met+++/++)
Method Description
c-Met-positive tumor cell line BxPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model Pancreatic ductal adenocarcinoma BxPC3 cells CVCL_0186
References
Ref 1 PEGylated antibody hydroxyl-bearing drug conjugates